Medical Condition News

RSS

Oxytocin hormone improves social behavior in autistic patients

Autism is a disease characterized by difficulties in communicating effectively with other people and developing social relationships. The team led by Angela Sirigu at the Centre de Neuroscience Cognitive (CNRS) has shown that the inhalation of oxytocin, a hormone known to promote mother-infant bonds and social relationships, significantly improved the abilities of autistic patients to interact with other individuals.

17 Feb 2010

Generx clinical development opportunities: bioRASI to assist Cardium

Cardium Therapeutics today announced that it has entered into an agreement with bioRASI, an international contract research organization, to assist Cardium in the evaluation of Generx clinical development opportunities within major newly-industrializing markets in Eastern Europe, Asia and Latin America, for patients with chronic coronary artery disease who are either not optimal candidates for or do not have access to costly angioplasty/stenting or cardiac bypass surgery procedures.

17 Feb 2010

TKS4 protein plays significant role in Frank-Ter Haar syndrome

An international team of investigators at Sanford-Burnham Medical Research Institute (Sanford-Burnham, formerly Burnham Institute for Medical Research), Nijmegen Centre for Molecular Life Sciences and other organizations have discovered that TKS4, a protein implicated in cancer metastasis, also plays a significant role in Frank-Ter Haar syndrome (FTHS), a rare fatal disorder.

17 Feb 2010

Rhubarb may have anti-cancer properties, but more research needed

Rhubarb contains natural chemicals called polyphenols that have been shown to kill cancer cells in the lab, or prevent their growth. Baking appears to greatly increase the levels of these chemicals, UK scientists have found, but Cancer Research UK cautioned against reading too much into these results.

17 Feb 2010

Adding daclizumab to standard treatment reduces enlarged brain lesions in patients with relapsing MS

An international team of researchers has found that adding a humanized monoclonal antibody called daclizumab to standard treatment reduces the number of new or enlarged brain lesions in patients with relapsing multiple sclerosis. This new study was published online Feb. 16, 2010, and in the March edition of the Lancet Neurology.

17 Feb 2010

Researchers adopt new technique to inhibit cancer growth

One of the difficulties of fighting cancer is that drugs often hit other non-cancerous cells, causing patients to get sick. But what if researchers could sneak cancer-fighting particles into just the cancer cells?

17 Feb 2010

Quintiles' anatomic pathology services now available in China to help develop effective cancer treatments

Quintiles today announced the availability of anatomic pathology services through its central laboratory in Beijing, China, to help biopharmaceutical companies develop more effective cancer treatments. These services complement assay development, digital pathology and core lab offerings available through the facility to help customers comply with China’s restrictions on tissue import/export.

17 Feb 2010

Certain patients with IBD at increased risk of developing colorectal cancer: AGA's new guidelines

Certain patients with inflammatory bowel disease (IBD), both ulcerative colitis and Crohn's disease of the colon, have an increased risk of developing colorectal cancer compared to individuals without IBD. A number of factors contribute to the increase in risk, which necessitates an individualized and sensible approach to surveillance in patients, according to a new medical position statement and technical review published by the American Gastroenterological Association in its official journal, Gastroenterology.

17 Feb 2010

Combination of daclizumab and interferon beta significantly reduces MS lesion formation

Biogen Idec and Facet Biotech Corporation today announced the publication of Phase 2 data showing that the addition of daclizumab to interferon beta (IFNβ) led to a significant reduction in the number of new or enlarged multiple sclerosis (MS) lesions when compared to IFNβ alone in patients with active relapsing forms of MS.

17 Feb 2010

Controlled utility study results of BGM Galectin-3 test for heart failure published in cardiology journal

BG Medicine, Inc. announced today that the results of a controlled study on the utility of its galectin-3 test in heart failure were published in the Journal Clinical Research in Cardiology, a peer-reviewed, international journal that publishes original research and review articles on clinical research studies in the field of cardiology.

17 Feb 2010

Delayed introduction of complementary baby foods may influence weight: Study

Benjamin Franklin's advice that "an ounce of prevention is worth a pound of cure" can easily be applied to today's most pressing health issue: obesity. Because taking off extra weight is an almost insurmountable challenge, preventing the progression of weight gain throughout life, especially childhood, is crucial to realizing optimal long-term health.

17 Feb 2010

New fluorescent probes improve tumor detection in mice

Building on his Nobel Prize-winning work creating fluorescent proteins that light up the inner workings of cells, a team of researchers led by Howard Hughes Medical Institute investigator Roger Tsien, PhD, professor of pharmacology, chemistry and biochemistry at the University of California, San Diego and the Moores UCSD Cancer Center has developed biological probes that can stick to and light up tumors in mice.

17 Feb 2010

Amgen and Centocor Ortho Biotech Products: FDA approves REMS for Aranesp, EPOGEN and PROCRIT ESAs

Amgen Inc. and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa) and PROCRIT® (Epoetin alfa).

17 Feb 2010

Special issue reviews current state of science in fetal therapy

Repairing birth defects in the womb. Inserting a tiny laser into the mother's uterus to seal off an abnormal blood flow and save fetal twins. Advancing the science that may allow doctors to deliver cells or DNA to treat sickle cell anemia and other genetic diseases before birth.

17 Feb 2010

Quark Pharmaceuticals' QPI-1002 receives orphan drug designation from FDA

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today that the US FDA has granted orphan drug designation for QPI-1002 (also referred to as "I5NP"), a synthetic siRNA targeting p53 mRNA for the prophylaxis of delayed graft function (DGF) in kidney transplant patients.

17 Feb 2010

TopoTarget pays Celldex Therapeutics $3M sublicense income over Belinostat co-development agreement

Celldex Therapeutics, Inc. today announced that it has received a sublicense income payment of $3 million from TopoTarget A/S as a result of the recent co-development and commercialization agreement between TopoTarget and Spectrum Pharmaceuticals, Inc. for Belinostat, a novel histone deacetylase (HDAC) inhibitor for the treatment of cancer.

17 Feb 2010

American Heart Association announces strategic goal to reduce stroke and cardiovascular diseases

Racial gaps exist in women's heart-health awareness, women's knowledge of heart attack warning signs requires attention and nearly half of women report they would not call 9-1-1 if they were having heart attack symptoms, according to new research published in Circulation: Cardiovascular Quality and Outcomes, a journal of the American Heart Association.

16 Feb 2010

Cancer Research UK, immatics Biotechnologies sign collaboration agreement to trial IMA950 vaccine for GMB

CANCER RESEARCH UK and Cancer Research Technology - the charity's development and commercialisation arm - have reached a collaboration agreement with immatics Biotechnologies to trial their new treatment vaccine, IMA950, for glioblastoma multiforme (GMB), one of the most common forms of brain cancer.

16 Feb 2010

Researchers use model organism to test new therapies for retinal degeneration

Research by Johns Hopkins sensory biologists studying fruit flies, has revealed a critical step in fly vision. Humans with problems in this same step suffer retinal dystrophies, which manifest as visual defects ranging from mild visual impairments to complete blindness.

16 Feb 2010

Eat 'heart-healthy' oats to prevent atherosclerosis

Nutritionist Mohsen Meydani, director of the Vascular Biology Laboratory at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University in Boston, Mass., led the research on the oat compounds, called avenanthramides. Meydani previously has shown that phenolic antioxidants in oats obstruct the ability of blood cells to stick to artery walls.

16 Feb 2010

Medical Condition News

Oxytocin hormone improves social behavior in autistic patients

Generx clinical development opportunities: bioRASI to assist Cardium

TKS4 protein plays significant role in Frank-Ter Haar syndrome

Rhubarb may have anti-cancer properties, but more research needed

Adding daclizumab to standard treatment reduces enlarged brain lesions in patients with relapsing MS

Researchers adopt new technique to inhibit cancer growth

Quintiles' anatomic pathology services now available in China to help develop effective cancer treatments

Certain patients with IBD at increased risk of developing colorectal cancer: AGA's new guidelines

Combination of daclizumab and interferon beta significantly reduces MS lesion formation

Controlled utility study results of BGM Galectin-3 test for heart failure published in cardiology journal

Delayed introduction of complementary baby foods may influence weight: Study

New fluorescent probes improve tumor detection in mice

Amgen and Centocor Ortho Biotech Products: FDA approves REMS for Aranesp, EPOGEN and PROCRIT ESAs

Special issue reviews current state of science in fetal therapy

Quark Pharmaceuticals' QPI-1002 receives orphan drug designation from FDA

TopoTarget pays Celldex Therapeutics $3M sublicense income over Belinostat co-development agreement

American Heart Association announces strategic goal to reduce stroke and cardiovascular diseases

Cancer Research UK, immatics Biotechnologies sign collaboration agreement to trial IMA950 vaccine for GMB

Researchers use model organism to test new therapies for retinal degeneration

Eat 'heart-healthy' oats to prevent atherosclerosis

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News